产后抑郁症不同药物治疗方案有效性与安全性的网状Meta分析
x

请在关注微信后,向客服人员索取文件

篇名: 产后抑郁症不同药物治疗方案有效性与安全性的网状Meta分析
TITLE: Efficacy and safety of pharmacological treatment strategies for postpartum depression:a network meta-analysis
摘要: 目的 比较产后抑郁症(PPD)不同药物治疗方案的有效性与安全性,为PPD的临床药物治疗提供依据。方法检索PubMed、Embase、CochraneLibrary、WebofScience、中国知网、中国生物医学文献服务系统、维普网和万方数据共8个数据库,收集传统抗抑郁药、神经活性类固醇、激素类药物、非甾体抗炎药、植物提取物及中药等治疗PPD的随机对照试验,检索时限均为建库至2025年10月20日。由2名研究者独立进行文献筛选、资料提取和偏倚风险评价。采用Stata17.0软件进行网状Meta分析,有效性结局以风险比(RR)及其95%置信区间(CI)为效应量,安全性结局采用Peto比值比(PetoOR)及其95%CI进行评价;采用累积排序概率曲线下面积(SUCRA)对各药物治疗方案的有效性和安全性进行排序。针对有效性结局,进一步将中药按具体方剂拆分为独立节点进行网状Meta分析,并通过剔除中药相关研究开展敏感性分析。结果最终纳入38项随机对照试验,共涉及3247例PPD患者,以及舍曲林、氟西汀、帕罗西汀、西酞普兰、艾司西酞普兰、文拉法辛、度洛西汀、阿米替林、去甲替林、马普替林、雌二醇、布瑞诺龙、舒拉诺龙、塞来昔布、藏红花、西红花苷及中药共17种药物治疗方案。网状Meta分析结果显示,与安慰剂相比,塞来昔布[RR=2.18,95%CI(1.28,3.71)]、去甲替林[RR=1.79,95%CI(1.07,3.00)]、中药[RR=1.77,95%CI(1.06,2.97)]、布瑞诺龙[RR=1.49,95%CI(1.18,1.87)]、舒拉诺龙[RR=1.48,95%CI(1.11,1.98)]及舍曲林[RR=1.47,95%CI(1.07,2.02)]的有效率较高(P<0.05);按SUCRA排序依次为塞来昔布(85.5%)、中药(75.5%)和去甲替林(72.2%)等,提示其有效率相对较高。中药方剂拆分分析结果显示,与安慰剂相比,柴胡疏肝散联合甘麦大枣汤及丹栀逍遥散的有效率均较高(P<0.05);剔除中药相关研究后的敏感性分析结果显示,塞来昔布仍位于有效性排序前列,但部分其他药物治疗方案的排序有所变化。安全性方面,舒拉诺龙[PetoOR=1.77,95%CI(1.15,2.71)]和马普替林[PetoOR=6.04,95%CI(1.03,35.34)]的不良事件发生风险均显著高于安慰剂(P<0.05);按SUCRA排序依次为布瑞诺龙(78.4%)、中药(75.8%)和西红花苷(70.5%)等,提示其安全性相对较高,而马普替林(4.6%)的安全性排名靠后。结论17种药物治疗方案中,塞来昔布、去甲替林、中药、布瑞诺龙、舒拉诺龙及舍曲林治疗PPD的有效率高于安慰剂;在安全性方面,舒拉诺龙和马普替林的安全性可能相对较差。
ABSTRACT: OBJECTIVE To compare the efficacy and safety of different pharmacological treatment strategies for postpartum depression (PPD) and to provide evidence for clinical pharmacotherapy of PPD.METHODS A total of eight databases were searched, including PubMed, Embase, Cochrane Library, Web of Science, CNKI, SinoMed, VIP, and Wanfang data from inception to October 20, 2025, to collect randomized controlled trials of traditional antidepressants, neuroactive steroids, hormonal agents, nonsteroidal anti-inflammatory drugs, plant extracts, and Chinese herbal medicine for PPD. Two reviewers independently performed literature screening, data extraction, and risk-of-bias assessment. Stata 17.0 software was used for network meta-analysis. For efficacy outcomes, risk ratio (RR) and its 95% confidence interval (CI) were used as effect measures; for safety outcomes, Peto odds ratio (Peto OR) and its 95% CI were used. The surface under the cumulative ranking curve (SUCRA) was used to rank the efficacy and safety of each pharmacological treatment strategy. For efficacy outcomes, Chinese herbal medicine was further separated into distinct nodes according to specific formulas for network meta-analysis, and a sensitivity analysis was performed by excluding Chinese herbal medicine-related studies.RESULTS A total of 38 randomized controlled trials involving 3 247 patients with PPD and 17 pharmacological treatment strategies were included: sertraline, fluoxetine, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, amitriptyline, nortriptyline, maprotiline, estradiol, brexanolone, zuranolone, celecoxib, saffron, crocin, and Chinese herbal medicine. The network meta-analysis showed that, compared with placebo, celecoxib [RR=2.18, 95%CI (1.28, 3.71)], nortriptyline [RR=1.79, 95%CI (1.07, 3.00)], Chinese herbal medicine [RR=1.77, 95%CI (1.06, 2.97)], brexanolone [RR=1.49, 95%CI (1.18, 1.87)], zuranolone [RR=1.48, 95%CI (1.11, 1.98)], and sertraline [RR=1.47, 95%CI (1.07, 2.02)] had higher response rates ( P <0.05); according to SUCRA rankings, celecoxib (85.5%), Chinese herbal medicine (75.5%), and nortriptyline (72.2%) ranked highest, suggesting relatively high response rates. The formula-separated analysis of Chinese herbal medicine showed that, compared with placebo, Chaihu shugan san combined with Ganmai dazao tang and Danzhi xiaoyao san both had higher response rates ( P <0.05). The sensitivity analysis excluding Chinese herbal medicine-related studies showed that celecoxib remained among the top-ranked interventions for efficacy, although the rankings of some other pharmacological treatment strategies changed. For safety, zuranolone [Peto OR=1.77, 95%CI (1.15, 2.71)] and maprotiline [Peto OR=6.04, 95%CI (1.03, 35.34)] were associated with a significantly higher risk of adverse events than placebo ( P <0.05); according to SUCRA rankings, brexanolone (78.4%), Chinese herbal medicine (75.8%), and crocin (70.5%) ranked highest, suggesting relatively high safety, whereas maprotiline (4.6%) had a low safety ranking.CONCLUSIONS Among the 17 pharmacological treatment strategies, celecoxib, nortriptyline, Chinese herbal medicine, brexanolone, zuranolone, and sertraline had higher response rates than placebo in the treatment of PPD; in terms of safety, zuranolone and maprotiline may have relatively poor safety profiles.
期刊: 2026年第37卷第21期
作者: 肖瑶;李丹蕾;赵天舒;谢萍
AUTHORS: XIAO Yao,LI Danlei,ZHAO Tianshu,XIE Ping
关键字: 产后抑郁症;有效性;安全性;网状Meta分析;药物治疗方案
KEYWORDS: postpartum depression;Efficacy;Safety;Network Meta-analysis;pharmacological treatment strategies
阅读数: 1 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!